Centessa Pharmaceuticals shares are trading higher after the company received Fast Track Designation from the FDA for its treatment of hemophilia B.
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals has received Fast Track Designation from the FDA for its hemophilia B treatment, leading to a rise in its share prices.
May 22, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Centessa Pharmaceuticals' stock price is trading higher after receiving FDA Fast Track Designation for its hemophilia B treatment.
The FDA Fast Track Designation is a significant regulatory milestone for Centessa Pharmaceuticals, as it accelerates the development and review process for its hemophilia B treatment. This positive news is likely to boost investor confidence in the company's prospects, leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100